Cardiovascular Disease

AIMS Trial Summary: Irbesartan in Marfan Syndrome

2019 AIMS TRIAL Irbesartan in Marfan syndrome Placebo-controlled, double-blind randomised trial Objective: To evaluate an angiotensin receptor blocker (ARB) compared with placebo among patients with confirmed Marfan syndrome. 192 patients Inclusion criteria: Patients with clinically confirmed Marfan syndrome, 6-40 years … Read More

AIM-HIGH Trial: Niacin + Statins in Hyperlipidemia

2011 AIM-HIGH TRIAL Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy Placebo controlled, randomized clinical trial Σ Objective: To assess if extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is … Read More

AIDA Trial Summary: Bioabsorbable Scaffolds for Routine PCI

2017 AIDA TRIAL Bioresorbable scaffolds versus metallic stents in routine PCI Prospective, multi-center, single-blind, randomized controlled trial M Objective: To assess if bioresorbable scaffolds superior to standard drug-eluting stents (DES) with regard to target-vessel failure in patients with stable or … Read More

AFIRE Trial Summary: Antithrombotics in AFib and CAD

2019 AFIRE TRIAL Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease Multicenter, open-label trial conducted in Japan Objective: To evaluate the use of antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease. 2236 patients 4.14 Inclusion … Read More

AFFIRM Trial Summary: Rate vs Rhythm Control for AFib

AFFIRM Trial: A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation Multicenter, parallel-group, randomized, controlled trial Objective: Among patients with atrial fibrillation and a high risk of stroke or death, what are the effects of rate … Read More

AF-CHF Trial Summary: Rhythm vs Rate Control for AFib and HF

AF-CHF: Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure Multicenter, prospective, randomized, controlled trial Objective: To assess if rhythm-control reduce CV mortality in patients with AF and HFrEF as compared to rate control. Patients with AF and … Read More

ACT Trial Summary: Acetylcysteine before Angiography

ACETYLCYSTEINE FOR PREVENTION OF RENAL OUTCOMES IN PATIENTS UNDERGOING ANGIOGRAPHY – ACT TRIAL Multicenter, Double-blind, Randomized, Placebo-controlled Trial STUDY OBJECTIVE: To Assess the use of acetylcysteine for preventing contrast-induced acute kidney injury in patients undergoing angiography 2308 Adults with ≥1 … Read More

ADAM VTE Trial Summary: Apixaban in Cancer-associated VTE

2019 ADAM VTE TRIAL Apixaban and dalteparin in active malignancy-associated venous thromboembolism multicenter, randomized, open-label superiority trial 287 patients 0 Objective: To study side effects of and compare apixaban and dalteparin in reducing blood clots in patients with cancer-related VTE. … Read More

ADAPTABLE Trial Summary: Aspirin Dosing in CV Disease

2013 ADAPTABLE TRIAL Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease Open-label, pragmatic design, randomized controlled trial M Objective: To assess whether a strategy of aspirin 325 mg/day would result in a lower risk of death from any cause, hospitalization … Read More

ACTIVE W Trial Summary: Clopidogrel + ASA vs. OAC for Atrial Fibrillation

2006 ACTIVE W TRIAL Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation Randomized, open treatment, controlled trial M Objective: Among patients with nonvalvular AF, how does combination aspirin/clopidogrel compare to warfarin in reducing the incidence of stroke, systemic embolism, … Read More